Please login to read the full article.
Scrip Regulatory Affairs
New US bill aims to alter first-filer measure for drug firms
22 November 2011
Donna Young
Please login to read the full article.
Not a subscriber ? Request a FREE Trial
Subscribe to Regulatory Affairs Pharma
RELATED CONTENT
NEWS
Scrip Regulatory Affairs News
- Congressional analysis: Pay-for-delay ban would save US taxpayers $4.8B over 10 years
- US user fee bill advances in Senate; House session postponed
- New US bill introduced to tackle pay-for-delay settlements between drug makers
- FTC: authorised generics benefit US consumers, but sometimes used as threat to competitors
Other Informa News
ANALYSIS
Regulatory Affairs Pharma Analysis
EDITORIALS
Other Informa Editorials
FEATURES
Regulatory Affairs Pharma Features
Other Informa Features
COMMENT
Other Informa Comments
